TRYNGOLZA is a new medication designed to help adults with familial chylomicronemia syndrome (FCS) manage their triglyceride levels. It is prescribed as an adjunct to a low-fat diet to reduce the risk of complications such as pancreatitis. TRYNGOLZA was approved on December 19, 2024.
What is the name of the drug, and what does it do?
TRYNGOLZA (pronounced trin-GOLE-zah) contains olezarsen, an antisense oligonucleotide that targets a protein called apolipoprotein C-III (apoC-III). By reducing apoC-III levels, TRYNGOLZA helps lower triglycerides in the blood, which are abnormally high in people with FCS.
How does it work?
TRYNGOLZA works by degrading the messenger RNA (mRNA) for apoC-III, a protein that inhibits the clearance of triglycerides from the bloodstream. By reducing apoC-III, the drug enhances the body’s ability to break down triglycerides, resulting in lower levels and improved lipid metabolism.
What did the research discover?
In a clinical trial involving patients with genetically confirmed FCS, TRYNGOLZA significantly reduced triglyceride levels. Participants who received TRYNGOLZA experienced a 42.5% reduction in fasting triglycerides compared to those who received a placebo. Additionally, the trial showed a lower incidence of acute pancreatitis among patients treated with TRYNGOLZA—5% compared to 30% in the placebo group. These results demonstrate TRYNGOLZA’s effectiveness in managing triglycerides and reducing pancreatitis risk.
What are some of the side effects?
The most common side effects of TRYNGOLZA include:
- Injection site reactions, such as redness or pain
- Decreased platelet count
- Joint pain (arthralgia)
Rare but serious side effects include hypersensitivity reactions such as facial swelling, rash, or trouble breathing. Patients should seek immediate medical attention if these occur.
What are the dosage recommendations, and how is it prescribed?
TRYNGOLZA is administered as an 80 mg subcutaneous injection once a month. It can be injected into the abdomen, the front of the thigh, or the back of the upper arm (by a healthcare provider or caregiver). Patients must follow a strict low-fat diet (less than 20 grams of fat daily) to maximize the medication’s benefits.
Source
Ionis Pharmaceuticals, Inc. Prescribing information for TRYNGOLZA (olezarsen). December 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218614s000lbl.pdf
